Literature DB >> 35924913

Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.

Nicholas M Smith1,2, Katie Rose Boissonneault1,2, Liang Chen3,4, Vidmantas Petraitis5, Ruta Petraitiene5, Xun Tao6, Jieqiang Zhou6, Yinzhi Lang6, Povilas Kavaliauskas5, Zackery P Bulman7, Patricia N Holden1,2, Raymond Cha1,2, Jürgen B Bulitta6, Barry N Kreiswirth3, Thomas J Walsh4,8,9,10, Brian T Tsuji1,2.   

Abstract

Metallo-β-lactamase (MBL)-producing Gram-negative bacteria cause infections associated with high rates of morbidity and mortality. Currently, a leading regimen to treat infections caused by MBL-producing bacteria is aztreonam combined with ceftazidime-avibactam. The purpose of the present study was to evaluate and rationally optimize the combination of aztreonam and ceftazidime-avibactam with and without polymyxin B against a clinical Klebsiella pneumoniae isolate producing NDM-1 and CTX-M by use of the hollow fiber infection model (HFIM). A novel de-escalation approach to polymyxin B dosing was also explored, whereby a standard 0-h loading dose was followed by maintenance doses that were 50% of the typical clinical regimen. In the HFIM, the addition of polymyxin B to aztreonam plus ceftazidime-avibactam significantly improved bacterial killing, leading to eradication, including for the novel de-escalation dosing strategy. Serial samples from the growth control and monotherapies were explored in a Galleria mellonella virulence model to assess virulence changes. Weibull regression showed that low-level ceftazidime resistance and treatment with monotherapy resulted in increased G. mellonella mortality (P < 0.05). A neutropenic rabbit pneumonia model demonstrated that aztreonam plus ceftazidime-avibactam with or without polymyxin B resulted in similar bacterial killing, and these combination therapies were statistically significantly better than monotherapies (P < 0.05). However, only the polymyxin B-containing combination therapy produced a statistically significant decrease in lung weights (P < 0.05), indicating a decreased inflammatory process. Altogether, adding polymyxin B to the combination of aztreonam plus ceftazidime-avibactam for NDM- and CTX-M-producing K. pneumoniae improved bacterial killing effects, reduced lung inflammation, suppressed resistance amplification, and limited virulence changes.

Entities:  

Keywords:  CTX-M; Enterobacterales; Klebsiella pneumoniae; New Delhi metallo-beta-lactamase; aztreonam; ceftazidime-avibactam; metallo-beta-lactamase; pharmacodynamics; pharmacokinetics; polymyxin B

Mesh:

Substances:

Year:  2022        PMID: 35924913      PMCID: PMC9487485          DOI: 10.1128/aac.00527-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  45 in total

1.  Filamentation by Escherichia coli subverts innate defenses during urinary tract infection.

Authors:  Sheryl S Justice; David A Hunstad; Patrick C Seed; Scott J Hultgren
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-15       Impact factor: 11.205

2.  Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.

Authors:  Henri Merdjan; Manickam Rangaraju; Antoine Tarral
Journal:  Clin Drug Investig       Date:  2015-05       Impact factor: 2.859

3.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits.

Authors:  T J Walsh; J Bacher; P A Pizzo
Journal:  Lab Anim Sci       Date:  1988-08

Review 4.  Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients.

Authors:  Jurgen B Bulitta; Cornelia B Landersdorfer; Alan Forrest; Silvia V Brown; Michael N Neely; Brian T Tsuji; Arnold Louie
Journal:  Curr Pharm Biotechnol       Date:  2011-12       Impact factor: 2.837

5.  Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Authors:  N M Smith; J R Lenhard; K R Boissonneault; C B Landersdorfer; J B Bulitta; P N Holden; A Forrest; R L Nation; J Li; B T Tsuji
Journal:  Clin Microbiol Infect       Date:  2020-02-12       Impact factor: 8.067

6.  Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  J Infect Dis       Date:  2004-09-24       Impact factor: 5.226

7.  Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.

Authors:  Brian T Tsuji; Cornelia B Landersdorfer; Justin R Lenhard; Soon-Ee Cheah; Visanu Thamlikitkul; Gauri G Rao; Patricia N Holden; Alan Forrest; Jürgen B Bulitta; Roger L Nation; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

8.  SOS response induction by beta-lactams and bacterial defense against antibiotic lethality.

Authors:  Christine Miller; Line Elnif Thomsen; Carina Gaggero; Ronen Mosseri; Hanne Ingmer; Stanley N Cohen
Journal:  Science       Date:  2004-08-12       Impact factor: 47.728

9.  A Tutorial on RxODE: Simulating Differential Equation Pharmacometric Models in R.

Authors:  W Wang; K M Hallow; D A James
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-12-19

10.  Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae.

Authors:  Tae Hwan Kim; Xun Tao; Bartolome Moya; Yuanyuan Jiao; Kari B Basso; Jieqiang Zhou; Yinzhi Lang; Dhruvitkumar S Sutaria; Alexandre P Zavascki; Afonso L Barth; Stephanie M Reeve; Herbert P Schweizer; Deanna Deveson Lucas; John D Boyce; Robert A Bonomo; Richard E Lee; Beom Soo Shin; Arnold Louie; George L Drusano; Jürgen B Bulitta
Journal:  mBio       Date:  2020-02-11       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.